Updates are available Correction dated 2022-08-11
Click to view Correction: https://doi.org/10.1038/s41416-022-01938-9
-
Authors
Gampala, Silpa
Shah, Fenil
Zhang, Chi
Rhodes, Steven D.
Babb, Olivia
Grimard, Michelle
Wireman, Randall S.
Rad, Ellie
Calver, Brian
Bai, Ren-Yuan
Staedtke, Verena
Hulsey, Emily L.
Saadatzadeh, M. Reza
Pollok, Karen E.
Tong, Yan
Smith, Abbi E.
Clapp, D. Wade
Tee, Andrew R.
Kelley, Mark R.
Fishel, Melissa L. http://orcid.org/0000-0002-9436-6382
- License Information
-
More Information
Article History
Received: 4 March 2020
Revised: 3 December 2020
Accepted: 5 January 2021
First Online: 3 March 2021
Change Date: 11 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-022-01938-9
Ethics approval and consent to participate
: All human specimens were collected with written informed consent, and with appropriate minimal risk institutional review board approval according to the approval and guidelines at Indiana University School of Medicine (Indianapolis, IN), and in accordance with the ethical standards of the Declaration of Helsinki. All cellular work was approved by Indiana University Institutional Biosafety Committee (#IN-1045). All animal work was conducted under approved Institutional Animal Care and Use Committee (IACUC) protocols and the Indiana University School of Medicine Laboratory Animal Resource Center (LARC) is accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC).
: Not applicable.
: We used publicly available data to analyse the genes that were upregulated with MPNST compared to benign neurofibromas and that data can be found here (ExternalRef removed). The previously published data that were used to determine Ref-1-regulated genes can be found in the GEO, accession number GSE99305. The RNA sequencing data in MPNST cells are currently being submitted to the GEO database.
: Mark R. Kelley has licensed APX3330 through Indiana University Research and Technology Corporation to Apexian Pharmaceuticals LLC. APX2009 and APX2014 are second-generation compounds from Apexian Pharmaceuticals. Apexian Pharmaceuticals had neither control nor oversight of the studies, interpretation or presentation of the data in this paper.
: M.L.F., C.Z., V.S. and D.W.C. supported by SPORE DRP P50 CA196519, M.L.F., M.R.K., K.E.P., C.Z. and D.W.C. supported by DOD Neurofibromatosis Research Program (W81XWH-19-1-0217) and IUSCC Cancer Center Support grant P30 CA082709. M.R.K. and M.L.F. were supported by grants from the National Institute of Health and National Cancer Institute R01CA167291 and R01CA167291-S1. Dr. Kelley was also supported by NIH/NCI grants R01CA205166, R01CA231267 and R01HL140961 and Dr. Fishel was supported by NIH/NCI grants U01HL143403, R01CA211098 and R01NF180045. M.L.F., M.R.K., K.E.P., S.D.R. and D.W.C. were additionally supported by the Riley Children’s Foundation and M.L.F. and M.R.K. through the Tom Wood Lexus Foundation. C.Z. was supported through NIGMS (1R01GM131399).
